Ignite Creation Date:
2025-12-24 @ 1:29 PM
Ignite Modification Date:
2026-01-26 @ 6:26 PM
Study NCT ID:
NCT01969695
Status:
COMPLETED
Last Update Posted:
2019-12-19
First Post:
2013-10-22
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
An Extension Study of ABT-199 in Subjects With Advanced Non-Hodgkin's Lymphoma
Sponsor:
AbbVie
Organization:
Study Overview
Official Title:
An Extension Study of Venetoclax in Subjects With Advanced Non-Hodgkin's Lymphoma
Status:
COMPLETED
Status Verified Date:
2019-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a Phase 1, open-label, multicenter, extension study. Subjects with non-Hodgkin's lymphoma (NHL) (excluding chronic lymphocytic lymphoma \[CLL\], small lymphocytic lymphoma \[SLL\], and mantle cell lymphoma \[MCL\]) who completed a prior ABT-199 study, or were active and assigned to ABT-199 when the study was completed, may roll over into this extension study. Subjects will receive ABT-199 during this study.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?: